Efficacy and tolerance of gabapentin in dystonia and hemifacial spasm: A pilot study;Eficacia y tolerancia de gabapentina en la distonía y el espasmo hemifacial: Estudio piloto

Revista de Neurologia

Volumn 33, Issue 5, 2001, Pages 408-410

  Linazasoro, Gurutz ^a  

^a HOSPITAL QUIRÓN   (Spain)

Author keywords

Dystonia; GABA; Gabapentin; Hemifacial spasm

Indexed keywords

EID: 0347749546     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3305.2001143     Document Type: Article

References (24)

1. Fahn S. Concept and classification of dystonia. Adv Neurol 1988; 50: 1-8.
2. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ. Epidemiology of focal and generalised dystonia in Rochester, Minnesota. Mov Disord 1988; 3: 188-94.
3. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991; 324: 1186-94.
4. Fahn S, Marsden CD. The treatment of dystonia. In Marsden CD, Fahn S, eds. Movement Disorders 2. London: Butterworths; 1987. p. 359-82.
5. Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985; 108: 463-83.
6. Eidelberg D. Abnormal brain networks in DYT1 dystonia. Adv Neurol 1998; 78: 127-33.
7. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 1990; 5: 100-8.
8. Mc Lean MJ. Gabapentin. Epilepsia 1995; 36 (Suppl 2): 73-86.
9. Gironell A, Kulisevski J, Barbanoj M, López-Villegas D, Hernández G, Pascual B. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol 1999; 56: 475-80.
10. Bandini F, Mazzella L. Tratamiento con gabapentina del espasmo hemifacial. Eur Neurol (Ed. Española) 1999; 2: 447-9.
11. Patel J, Naritoku DK. Gabapentin for the treatment of hemifacial spasm. Clin Neuropharmacol 1996; 19: 185-8.
12. Reves AL, So EL, Sharbrough FW, Krahn LE. Movement disorders associated with the use of gabapentin. Epilepsia 1996; 37: 988-90.
13. Chudnow RS, Dewey RB Jr, Lawson CR. Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients. Arch Neurol 1997; 54: 910-2.
14. Buetefisch CM, Gutiérrez A, Gutmann L. Choreoathetotic movements: a possible side effect of gabapentin. Neurology 1996; 46 851-2.
15. Palomeras E, Sanz P, Cano A, Fossas P. Dystonia in a patient treated with propranolol and gabapentin. Arch Neurol 2000; 57: 570-1.
16. Chan P, de Marinis A, Barrientos N. Gabapentin and motor fluctuations in Parkinson's disease. Mov Disord 1997; 12: 608.
17. Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med 1997; 102: 60-6.
18. Richter A, Loscher W. Gabapentin decreases the severity of dystonia at low doses in a genetic animal model of paroxysmal dystonic choreoathetosis. Eur J Pharmacol 1999; 369; 335-8.
19. Chudnow RS, Mimbela RA, Owen DB, Roach ES. Gabapentin for familial paroxysmal dystonic choreoathetosis. Neurology 1997; 49: 1441-2.
20. Taylor CP. Gabapentin: Mechanisms of action. In Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press; 1995. p. 829-41.
21. Greene PE, Fahn S. Baclofen in the treatment of idiopathic dystonia in children. Mov Disord 1992; 7: 48-52.
22. Gollomp SM, Fahn S, Burke RE, Reches A, Ilson J. Therapeutic trials in Meige syndrome. Adv Neurol 1983; 37: 207-13.
23. Carella FF, Girotti F, Scigliano G, Caraceni T, Joder AM, Schlechter PJ. Double-blind study of oral gamma-vinyl-GABA in the treatment of dystonia. Neurology 1986; 36: 98-100.
24. Burke RE, Fahn S, Marsden CD, Bressman SB, Moskowitz C, Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73-7.